Livzon Pharmaceutical Group Inc. (SHE:000513)
26.41
-0.35 (-1.31%)
Aug 31, 2026, 3:04 PM CST
SHE:000513 Revenue
Livzon Pharmaceutical Group had revenue of 2.13B CNY in the quarter ending June 30, 2026, a decrease of -31.14%. This brings the company's revenue in the last twelve months to 10.75B, down -8.93% year-over-year. In the year 2025, Livzon Pharmaceutical Group had annual revenue of 12.02B with 1.76% growth.
Revenue (ttm)
10.75B
Revenue Growth
-8.93%
P/S Ratio
1.93
Revenue / Employee
1.21M
Employees
8,878
Market Cap
20.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.02B | 208.01M | 1.76% |
| Dec 31, 2024 | 11.81B | -617.70M | -4.97% |
| Dec 31, 2023 | 12.43B | -199.54M | -1.58% |
| Dec 31, 2022 | 12.63B | 565.72M | 4.69% |
| Jan 1, 2022 | 12.06B | 1.54B | 14.67% |
| Jan 1, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harbin Pharmaceutical Group | 16.14B |
| Tasly Pharmaceutical Group | 8.15B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.12B |
| Kangmei Pharmaceutical | 4.97B |
| Chengdu Kanghong Pharmaceutical Group | 4.31B |
| Betta Pharmaceuticals | 3.85B |
| Shanghai Haoyuan Chemexpress | 3.21B |
| Jilin Aodong Pharmaceutical Group | 2.24B |
Livzon Pharmaceutical Group News
- 10 days ago - Livzon Pharmaceutical Group Quarterly report: Q2 2026 - Filings
- 4 months ago - Livzon Pharmaceutical Group Quarterly report: Q1 2026 - Filings
- 5 months ago - Livzon Pharmaceutical Group Annual report: Q4 2025 - Filings
- 11 months ago - Livzon Pharmaceutical Group Quarterly report: Q3 2025 - Filings